サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1771740

肝疾患治療薬の市場規模、シェア、動向分析レポート：製品別、疾患別、地域別、セグメント予測、2025年～2033年

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Antiviral Drugs, Vaccines, Chemotherapy), By Disease (Hepatitis, Autoimmune Diseases), By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
肝疾患治療薬の市場規模、シェア、動向分析レポート：製品別、疾患別、地域別、セグメント予測、2025年～2033年
出版日: 2025年06月19日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肝疾患治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、肝疾患治療薬の世界市場規模は2033年までに402億9,000万米ドルとなり、2025～2033年のCAGRは7.9％を記録すると予測されています。

主要促進要因は、肝細胞がんのような肝疾患の増加と、この種の疾患患者の膨大な未開拓ニーズです。加えて、世界の高齢者の増加が、将来的な市場需要を増大させると推定されます。

バイオテクノロジーや製薬産業による研究開発への莫大な支出や、強力なパイプラインの利用可能性は、将来期間における肝疾患治療薬市場の成長を後押しする主要因として期待されています。政府や大企業のワクチン接種プログラムは、病気や予防に対する意識を高めており、市場の成長を後押ししています。

市場は製品と地域に二分されます。新製品が急速に発売され、市場の成長を後押ししています。市場の成長は、主要企業間の戦略的提携やジョイントベンチャー、今後の国々におけるヘルスケアに対する意識の高まりによって後押しされています。

肝疾患治療薬市場のレポートハイライト

  • 慢性ウイルス性肝炎の世界の有病率の高さ、HBVの治療期間の長さ、HCV DAAsの割高な価格設定により、2024年には抗ウイルス薬部門が39.84%の最大売上シェアで市場を独占します。
  • 肝炎セグメントは2024年に40.44%の最大売上シェアで市場を独占しました。慢性肝炎の広範な負担と抗ウイルス治療の臨床的成功に起因し、肝炎セグメントは引き続き主要な市場促進要因です。
  • 北米は、肝疾患の有病率の上昇、人口の高齢化、画期的な治療法が牽引し、2024年には世界収益の39.87%を占め、肝疾患治療薬市場で最大のシェアを占めました。
  • アジア太平洋の肝疾患治療薬市場は、B型肝炎とC型肝炎の高い有病率、NAFLD患者の増加、ヘルスケアインフラの改善によって、予測期間中に9.19%のCAGRで最も急速に成長すると予測されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肝疾患治療薬市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 肝疾患治療薬市場：製品ビジネス分析

  • 製品市場シェア、2025年と2033年
  • 製品セグメントダッシュボード
  • 市場規模と予測、製品別動向分析、2021～2033年
  • 抗ウイルス薬
  • ワクチン
  • 化学療法
  • 標的療法
  • 免疫抑制剤
  • 免疫グロブリン
  • コルチコステロイド
  • その他

第5章 肝疾患治療薬市場：疾患ビジネス分析

  • 疾患市場シェア、2025年と2033年
  • 疾患セグメントダッシュボード
  • 市場規模と予測、疾患別動向分析、2021～2033年
  • 肝炎
  • 自己免疫疾患
  • 非アルコール性脂肪性肝疾患（NAFLD）
  • がん
  • 遺伝性疾患
  • その他

第6章 肝疾患治療薬市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2025年と2033年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2021～2033年
  • 北米
    • 国別、2021～2033年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • GSK plc
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global liver disease therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 5. Global liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 6. North America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 8. North America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 9. U.S. liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 10. U.S. liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 11. Canada liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 12. Canada liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 13. Mexico liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 14. Mexico liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 15. Europe liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 17. Europe liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 18. UK liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 19. UK liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 20. Germany liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 21. Germany liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 22. France liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 23. France liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 24. Italy liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 25. Italy liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 26. Spain liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 27. Spain liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 28. Norway liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 29. Norway liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 30. Denmark liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 31. Denmark liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 32. Sweden liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 33. Sweden liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 37. Japan liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 38. Japan liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 39. China liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 40. China liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 41. India liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 42. India liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 43. Australia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 44. Australia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 45. South Korea liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 46. South Korea liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 47. Thailand liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 48. Thailand liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 49. Latin America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 51. Latin America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 52. Brazil liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 53. Brazil liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 54. Argentina liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 55. Argentina liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 59. South Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 60. South Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 63. UAE liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 64. UAE liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 65. Kuwait liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 66. Kuwait liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Liver disease therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Liver disease therapeutics market dynamics
  • Fig. 12 Liver disease therapeutics market: Porter's five forces analysis
  • Fig. 13 Liver disease therapeutics market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Antiviral drugs market, 2021 - 2033 (USD Million)
  • Fig. 16 Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 17 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 18 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 Immunosuppressants market, 2021 - 2033 (USD Million)
  • Fig. 20 Immunoglobulins market, 2021 - 2033 (USD Million)
  • Fig. 21 Corticosteroids market, 2021 - 2033 (USD Million)
  • Fig. 22 Other products market, 2021 - 2033 (USD Million)
  • Fig. 23 Disease market, 2021 - 2033 (USD Million)
  • Fig. 24 Hepatitis market, 2021 - 2033 (USD Million)
  • Fig. 25 Autoimmune diseases market, 2021 - 2033 (USD Million)
  • Fig. 26 Non-alcoholic Fatty Liver Disease (NAFLD) market, 2021 - 2033 (USD Million)
  • Fig. 27 Cancer market, 2021 - 2033 (USD Million)
  • Fig. 28 Genetic disorders market, 2021 - 2033 (USD Million)
  • Fig. 29 Other diseases market, 2021 - 2033 (USD Million)
  • Fig. 30 Liver disease therapeutics market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Europe liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark country dynamics
  • Fig. 55 Denmark liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Asia Pacific liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 Latin America liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 MEA liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework
目次
Product Code: 978-1-68038-540-3

Liver Disease Therapeutics Market Growth & Trends:

The global liver disease therapeutics market size is expected to be valued at USD 40.29 billion by 2033, registering a CAGR of 7.9% from 2025 to 2033, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Liver Disease Therapeutics Market Report Highlights:

  • The antiviral drugs segment dominated the market with the largest revenue share of 39.84% in 2024 due to the high global prevalence of chronic viral hepatitis, long treatment durations for HBV, and premium pricing for HCV DAAs.
  • The hepatitis segment dominated the market with the largest revenue share of 40.44% in 2024, attributed to the widespread burden of chronic hepatitis and the clinical success of antiviral treatments, the hepatitis segment remains a major market driver.
  • North America held the largest share of the liver disease therapeutics market in 2024, accounting for 39.87% of global revenue, driven by the rising prevalence of liver disease, aging populations, and breakthrough therapies.
  • The liver disease therapeutics market in Asia Pacific is projected to grow at the fastest CAGR of 9.19% over the forecast period, fueled by the high prevalence of hepatitis B and C, rising NAFLD cases, and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Liver Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Liver Disease Therapeutics Market: Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Antiviral Drugs
    • 4.4.1. Antiviral Drugs Market, 2021 - 2033 (USD Million)
  • 4.5. Vaccines
    • 4.5.1. Vaccines Market, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy
    • 4.7.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
  • 4.8. Immunosuppressants
    • 4.8.1. Immunosuppressants Market, 2021 - 2033 (USD Million)
  • 4.9. Immunoglobulins
    • 4.9.1. Immunoglobulins Market, 2021 - 2033 (USD Million)
  • 4.10. Corticosteroids
    • 4.10.1. Corticosteroids Market, 2021 - 2033 (USD Million)
  • 4.11. Other Products
    • 4.11.1. Other Products Market, 2021 - 2033 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Business Analysis

  • 5.1. Disease Market Share, 2025 & 2033
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. Hepatitis
    • 5.4.1. Hepatitis Market, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
  • 5.6. Non-alcoholic Fatty Liver Disease (NAFLD)
    • 5.6.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market, 2021 - 2033 (USD Million)
  • 5.7. Cancer
    • 5.7.1. Cancer Market, 2021 - 2033 (USD Million)
  • 5.8. Genetic Disorders
    • 5.8.1. Genetic Disorders Market, 2021 - 2033 (USD Million)
  • 5.9. Other Diseases
    • 5.9.1. Other Diseases Market, 2021 - 2033 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Gilead Sciences, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AbbVie Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bristol-Myers Squibb Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. F. Hoffmann-La Roche Ltd
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Takeda Pharmaceutical Company Limited.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck & Co., Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Novartis AG
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Pfizer Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. GSK plc
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives